CO2017004789A2 - Formulación inhalable - Google Patents

Formulación inhalable

Info

Publication number
CO2017004789A2
CO2017004789A2 CONC2017/0004789A CO2017004789A CO2017004789A2 CO 2017004789 A2 CO2017004789 A2 CO 2017004789A2 CO 2017004789 A CO2017004789 A CO 2017004789A CO 2017004789 A2 CO2017004789 A2 CO 2017004789A2
Authority
CO
Colombia
Prior art keywords
inhalable formulation
active pharmaceutical
pharmaceutical ingredient
propellant
inhalable
Prior art date
Application number
CONC2017/0004789A
Other languages
English (en)
Inventor
Mukul Dalvi
Jacquelyn Mccabe
Original Assignee
Teva Branded Pharmaceutical Products R&D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Branded Pharmaceutical Products R&D Inc filed Critical Teva Branded Pharmaceutical Products R&D Inc
Publication of CO2017004789A2 publication Critical patent/CO2017004789A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Esta invención proporciona un proceso para la preparación de un ingrediente farmacéutico activo inhalable que comprende las etapas de calentar una suspensión de un ingrediente farmacéutico activo en un propelente licuado en un recipiente, la evaporación del propelente y recoger el polvo resultante.
CONC2017/0004789A 2014-10-16 2017-05-12 Formulación inhalable CO2017004789A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064684P 2014-10-16 2014-10-16
PCT/US2015/055916 WO2016061445A1 (en) 2014-10-16 2015-10-16 Inhalable formulation

Publications (1)

Publication Number Publication Date
CO2017004789A2 true CO2017004789A2 (es) 2017-09-20

Family

ID=54361199

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0004789A CO2017004789A2 (es) 2014-10-16 2017-05-12 Formulación inhalable

Country Status (15)

Country Link
US (1) US10653704B2 (es)
EP (1) EP3206667A1 (es)
JP (1) JP6653323B2 (es)
KR (1) KR20170070151A (es)
CN (1) CN107106515A (es)
AR (1) AR102304A1 (es)
AU (1) AU2015331912A1 (es)
BR (1) BR112017007589A2 (es)
CA (1) CA2963143A1 (es)
CO (1) CO2017004789A2 (es)
EA (1) EA201790832A1 (es)
IL (1) IL251664A0 (es)
MX (1) MX2017004765A (es)
PE (1) PE20170919A1 (es)
WO (1) WO2016061445A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
EP0616525B1 (en) 1991-12-12 1995-09-27 Glaxo Group Limited Pharmaceutical aerosol formulation
GB9526392D0 (en) 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
DE10043509A1 (de) 2000-09-01 2002-03-14 Asta Medica Ag Feste Peptidzubereitungen für die Inhalation und deren Herstellung
SE0004750D0 (sv) 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
US20050152845A1 (en) * 2002-02-04 2005-07-14 Keith Biggadike Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
WO2005081833A2 (en) 2004-02-24 2005-09-09 Microdose Technologies, Inc. Synthetic jet based medicament delivery method and apparatus
WO2007008427A2 (en) 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
US8196576B2 (en) 2007-02-28 2012-06-12 Microdose Therapeutx, Inc. Inhaler
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
AU2015331915A1 (en) * 2014-10-16 2017-05-25 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder formulation

Also Published As

Publication number Publication date
BR112017007589A2 (pt) 2018-01-30
KR20170070151A (ko) 2017-06-21
US10653704B2 (en) 2020-05-19
EA201790832A1 (ru) 2017-09-29
JP2017534611A (ja) 2017-11-24
JP6653323B2 (ja) 2020-02-26
AR102304A1 (es) 2017-02-15
WO2016061445A1 (en) 2016-04-21
US20170239269A1 (en) 2017-08-24
AU2015331912A1 (en) 2017-05-25
EP3206667A1 (en) 2017-08-23
PE20170919A1 (es) 2017-07-12
CN107106515A (zh) 2017-08-29
IL251664A0 (en) 2017-06-29
MX2017004765A (es) 2017-07-27
CA2963143A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
ZA201706227B (en) Vaporizer for vaporizing an active ingredient
IL273507A (en) Methods, devices and systems for administering active substances through the lungs
BR112016030883A2 (pt) Dispositivo de aerossolização, e, métodos para dispensação de um medicamento aerossolizado e para uso de um dispositivo de aerossol.
HUE065938T2 (hu) Szubsztituált indazolok, eljárás ezek elõállítására, ezeket tartalmazó gyógyszerkészítmények, valamint ezek alkalmazása gyógyszerkészítmények elõállítására
CO2018003558A2 (es) Método de cristalización y biodisponibilidad
EP3160565A4 (en) Methods, devices and systems for pulmonary delivery of active agents
EP3160554A4 (en) Methods, devices and systems for pulmonary delivery of active agents
EP3081222A4 (en) Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
EP3094343A4 (en) Rapid action insulin formulations and pharmaceutical delivery systems
GB201411465D0 (en) Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer
PH12016501841A1 (en) Immunosuppressant formulation
SG11201610636VA (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
CO2017004789A2 (es) Formulación inhalable
GB201707679D0 (en) Device for delivering medicaments or active ingredients
WO2015195711A3 (en) Method and devices for manufacturing and delivering of aerosolized formulations
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
ZA201701820B (en) Biocide and/or phytosanitary formulation for aerosol use, made of active biodegradable non-residual substances
MX2017003653A (es) Metodo para acondicionar un dianhidrohexitol, disolucion acuosa de dianhidrohexitol acondicionado, y usos de la misma.
EP3310786A4 (en) Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
IN2014DE00111A (es)
AR101563A1 (es) Terapia de combinación de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano
GB201414271D0 (en) Composition for delivery of an active pharmaceutical substance and method of preparing same
EP3182926A4 (en) Corneal implant storage, packaging, and delivery devices
UA89548U (ru) Фармацевтическая аэрозольная композиция для лечения бактериальных вагинозов